Drug intelligence / Profile preview

caffeine + losartan + midazolam + omeprazole

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Intranasal
01

Overview

This is a combination of four active pharmaceutical ingredients: - **Caffeine** is a central nervous system stimulant commonly used to increase alertness and reduce fatigue. It acts primarily as an adenosine receptor antagonist. - **Losartan** is an angiotensin II receptor blocker (ARB) used mainly for the treatment of hypertension and to protect the kidneys from damage due to diabetes. It works by blocking the action of angiotensin II, resulting in vasodilation. - **Midazolam** is a short-acting benzodiazepine with anxiolytic, amnestic, hypnotic, anticonvulsant, and muscle relaxant properties. It acts as a positive allosteric modulator at GABA-A receptors. - **Omeprazole** is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly inhibiting the H^+/K^+-ATPase enzyme system in gastric parietal cells[2][4][5][6][8]. There are no known approved pharmaceutical products or brand names containing this exact combination; it appears to be an investigational or research-use-only mixture rather than a marketed drug product.

02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)ADORA3 (Adenosine A3 receptor)AGTR1 (Angiotensin II Type-1 receptor)BZD site (GABA-A receptor benzodiazepine site)ADOR (Adenosine receptors)GABAA (Gamma-aminobutyric acid receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on caffeine + losartan + midazolam + omeprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on caffeine + losartan + midazolam + omeprazole.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call